Drugs / BI 836826
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03343678 | Jan → May 2018 | B-cell chronic lymphocytic leukemia | Boehringer Ingelheim | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02759016 | Jun 2016 → Jun 2019 | B-cell chronic lymphocytic leukemia | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02538614 | Dec 2015 → Jul 2017 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1 | NCT01403948 | Aug 2011 → Nov 2017 | non-Hodgkin lymphoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01296932 | Feb 2011 → May 2017 | B-cell chronic lymphocytic leukemia | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02624492 | Jan 2016 → Mar 2018 | diffuse large B-cell lymphoma | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 836826 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01403948 ↗ |
| Known as | Mab 37.1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594531 ↗ |
| Modality | Monoclonal antibody | “BI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37” PMID 32172489 ↗ Mar 2020 |
| Route | Intravenous | “administered as an intravenous infusion.” NCT01296932 ↗ |
| Target | CD37 | “targeting CD37” PMID 32172489 ↗ Mar 2020 |